Using the CANCERPLEX‐JP 435‐gene panel, we profiled the genomic landscape of 49 HER2‐positive and 31 HER2‐negative gastric cancer patients who were enrolled in a prospective phase II trial. This evidence concerns the gene ERBB2 and gastric cancer.